2-(1-(phenylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(1-(phenylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazole
• 英文别名: 2-[1-(benzenesulfonyl)piperidin-4-yl]-1H-benzimidazole
• 化学式: C₁₈H₁₉N₃O₂S
• 分子量: 341.434
• InChiKey: BGAYELMDHYVQTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  74.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  苯磺酰氯 、 2-(4-哌啶)-1H-苯并咪唑 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到2-(1-(phenylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazole
  参考文献：
  名称：

  [EN] SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF
  [FR] ANTAGONISTES À PETITES MOLÉCULES DE LA MODIFICATION LIÉE AU SUMO DE CRMP2 ET LEURS UTILISATIONS

  摘要：

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有哌啶基苯并咪唑结构的小分子，其作为小泛素样修饰物（SUMO）相关修饰（SUMOylation）的抗体，用作治疗与电压门控钠通道1.7（Nav1.7）相关的瘙痒、嗅觉丧失、偏头痛事件和/或疼痛（例如，神经病性疼痛）的治疗药物。

  公开号：

  WO2018144900A1

文献信息

• Small molecule antagonists of sumo related modification of CRMP2 and uses thereof
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US11208397B2

  公开（公告）日：2021-12-28

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

  本发明属于药物化学领域。特别是，本发明涉及一类具有哌啶基苯并咪唑结构的新的小分子，它们可作为塌缩素反应介质蛋白 2（CRMP2）的小泛素样修饰剂（SUMO）相关修饰（SUMOylation）的拮抗剂，并可用作治疗与电压门控钠通道 1.7（Nav1.7）相关的痒、嗅觉障碍、偏头痛事件和/或疼痛（如神经性疼痛）的药物。
• 10.1039/d4ob00878b
  作者：Venkat Shivaji Ramarao、Solanke, Jayshree Nandkumar、Chatterjee, Rana、Gat, Savita、Dhayalan, Vasudevan、Dandela, Rambabu

  DOI：10.1039/d4ob00878b

  日期：——

  A simple and novel approach has been developed for the synthesis of sulfonamides from N-hydroxy sulfonamide. Notably, the iodine-tert-butyl hydroperoxide (TBHP) system efficiently promoted the sulfonylation reactions of N-hydroxy sulfonamides and amines via the oxidative cleavage of an S–N bond. A variety of aryl sulfonamides were prepared in moderate to good yields using readily available starting

  开发了一种简单而新颖的方法用于从N-羟基磺酰胺合成磺酰胺。值得注意的是，碘-叔丁基过氧化氢（TBHP）系统通过S-N键的氧化断裂有效促进了N-羟基磺酰胺和胺的磺酰化反应。使用易于获得的起始原料和生物质衍生的 2-MeTHF 溶剂，以中等至良好的收率制备了各种芳基磺酰胺。该方法具有无金属试剂、介质环境友好、试剂成本低、底物范围广、条件温和等优点。
• SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20200277271A1

  公开（公告）日：2020-09-03

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).
• [EN] SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF<br/>[FR] ANTAGONISTES À PETITES MOLÉCULES DE LA MODIFICATION LIÉE AU SUMO DE CRMP2 ET LEURS UTILISATIONS
  申请人：UNIV ARIZONA

  公开号：WO2018144900A1

  公开（公告）日：2018-08-09

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有哌啶基苯并咪唑结构的小分子，其作为小泛素样修饰物（SUMO）相关修饰（SUMOylation）的抗体，用作治疗与电压门控钠通道1.7（Nav1.7）相关的瘙痒、嗅觉丧失、偏头痛事件和/或疼痛（例如，神经病性疼痛）的治疗药物。